Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-6
Publisher
Informa UK Limited
Online
2022-06-21
DOI
10.1080/14712598.2022.2093106
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial
- (2022) Matthias Augustin et al. BRITISH JOURNAL OF DERMATOLOGY
- Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients
- (2021) Han Cao et al. Lipids in Health and Disease
- Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
- (2021) Akshitha Thatiparthi et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Is Metformin a Possible Beneficial Treatment for Psoriasis? A Scoping Review
- (2021) Ana Maria Alexandra Stanescu et al. Journal of Personalized Medicine
- Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?
- (2021) Marianne de Brito et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study
- (2021) Federico Pirro et al. CLINICAL DRUG INVESTIGATION
- Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
- (2021) Riccardo G. Borroni et al. ACTA DERMATO-VENEREOLOGICA
- Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations
- (2021) Marco Galluzzo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
- (2020) Paolo Gisondi et al. Frontiers in Pharmacology
- IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
- (2020) Esther von Stebut et al. Frontiers in Immunology
- Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core
- (2020) Harry Choi et al. Circulation-Cardiovascular Imaging
- A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic
- (2020) K. Hansel et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
- (2019) Youssef A Elnabawi et al. CARDIOVASCULAR RESEARCH
- Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
- (2019) April Armstrong et al. Dermatology and Therapy
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
- (2019) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The role of non-resolving inflammation in atherosclerosis
- (2018) Canan Kasikara et al. JOURNAL OF CLINICAL INVESTIGATION
- The mechanism of skin lipids influencing skin status
- (2018) Yan Jia et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Psoriasis and the risk of diabetes: A prospective population-based cohort study
- (2018) Marilyn T. Wan et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study
- (2018) J.M. Fernández-Armenteros et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks
- (2018) Esther von Stebut et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events
- (2017) Alexander Egeberg et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases
- (2017) Marwa Chehimi et al. Journal of Clinical Medicine
- Interleukin 17A in atherosclerosis – Regulation and pathophysiologic effector function
- (2017) Johannes Nordlohne et al. CYTOKINE
- Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational StudySignificance
- (2015) Haley B. Naik et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Patients with psoriasis are insulin resistant
- (2015) Mette Gyldenløve et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Interleukin 23 Levels Are Increased in Carotid Atherosclerosis
- (2015) Azhar Abbas et al. STROKE
- Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study
- (2014) Roberta Ramonda et al. JOINT BONE SPINE
- Cardiac fibroblasts mediate IL-17A–driven inflammatory dilated cardiomyopathy
- (2014) Lei Wu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Psoriasis Is Not Associated with Atherosclerosis and Incident Cardiovascular Events: The Rotterdam Study
- (2013) Emmilia A. Dowlatshahi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Lysophosphatidylcholine Triggers TLR2- and TLR4-Mediated Signaling Pathways but Counteracts LPS-Induced NO Synthesis in Peritoneal Macrophages by Inhibiting NF-κB Translocation and MAPK/ERK Phosphorylation
- (2013) Alan Brito Carneiro et al. PLoS One
- Interleukin-12 Is Associated With Arterial Stiffness in Healthy Individuals
- (2012) K. Yong et al. AMERICAN JOURNAL OF HYPERTENSION
- Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction
- (2012) Tabassome Simon et al. EUROPEAN HEART JOURNAL
- Systemic and Vascular Inflammation in Patients With Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography –Computed Tomography (FDG-PET/CT)
- (2011) Nehal N. Mehta ARCHIVES OF DERMATOLOGY
- Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E–Deficient Mice
- (2011) Meena S. Madhur et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient Mice
- (2010) Emily Smith et al. CIRCULATION
- Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients
- (2010) Gianluigi Mazzoccoli et al. Internal and Emergency Medicine
- Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis
- (2010) Yoichi Inaba et al. INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
- (2009) N. N. Mehta et al. EUROPEAN HEART JOURNAL
- Oxidative stress in the pathogenesis of psoriasis
- (2009) Qiang Zhou et al. FREE RADICAL BIOLOGY AND MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started